Company Analysis
Sign in

Moderna, Inc. (MRNA)

Nasdaq: MRNA · Biological Products, (No Diagnostic Substances) · Cambridge, MA · filing with the SEC since 2016
Full chart Alerts Compare
Grade5.7
◀ Past 7.3● Present 6.0▶ Future 3.6
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

271 patents granted to the 6 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Moderna, Inc.’s names, not what it holds today.

Patents granted
271
271 utility, 1976 to Dec 31, 2025
Granted in 2025
37
Against 31 in 2024 and 27 in 2023
Applications published
634
65 of them in 2025
Names they are printed under
6
a subsidiary, a former name
By yearGrantedApplications published
'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals106
Biotechnology21
Organic fine chemistry8
Measurement2
Basic materials chemistry1
Chemical engineering1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name6 counted
ModernaTX, Inc. a subsidiary
US, as the owner printed on each patent. 27 more under the same name are not counted (printed in GB)
234 granted
213 published
ModernaTX, Inc. a subsidiary
named as the applicant on its applications, in US. 1 more under the same name are not counted (printed in MA)
0 granted
275 published
Moderna Therapeutics, Inc. a former name
US, as the owner printed on each patent
34 granted
74 published
Moderna Therapeutics, Inc. a former name
named as the applicant on its applications, in US
0 granted
66 published
Moderna Enzymatics Co., Ltd. a subsidiary
named as the applicant on its applications, in JP
0 granted
6 published
Moderna Enzymatics Co., Ltd. a subsidiary
JP, as the owner printed on each patent
3 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 30, 202512,508,278Lipid nanoparticle compositions and methods of formulating the samePharmaceuticalsModernaTX, Inc.
Dec 23, 202512,502,431Delivery and formulation of engineered nucleic acidsPharmaceuticalsModernaTX, Inc.
Dec 16, 202512,496,561Vortex mixers and associated methods, systems, and apparatuses thereofChemical engineeringModernaTX, Inc.
Dec 16, 202512,496,358Modified nucleosides, nucleotides, and nucleic acids, and uses thereofBiotechnologyModernaTX, Inc.
Dec 9, 202512,491,260Compositions and methods for delivery of agentsPharmaceuticalsModernaTX, Inc.
Nov 4, 202512,460,259Fed-batch in vitro transcription processBiotechnologyModernaTX, Inc.
Oct 28, 202512,453,766RSV RNA vaccinesPharmaceuticalsModernaTX, Inc.
Sep 30, 202512,428,577Methods of monitoring in vitro transcription of mRNA and/or post-in vitro transcription processesBasic materials chemistryModernaTX, Inc.
Sep 23, 202512,419,957Delivery and formulation of engineered nucleic acidsPharmaceuticalsModernaTX, Inc.
Sep 9, 202512,409,347Betacoronavirus mRNA vaccinesPharmaceuticalsModernaTX, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388963PRIMER DESIGN FOR CELL-FREE DNA PRODUCTIONBiotechnologyModernaTX, Inc.
Dec 11, 20252025/0375391LIPID NANOPARTICLE COMPOSITIONS COMPRISING SURFACE LIPID DERIVATIVES AND RELATES USESPharmaceuticalsModernaTX, Inc.
Dec 11, 20252025/0375389LIPID NANOPARTICLE COMPOSITIONS COMPRISING PHOSPHOLIPID DERIVATIVES AND RELATED USESPharmaceuticalsModernaTX, Inc.
Dec 4, 20252025/0369028CONTINUOUS IN VITRO TRANSCRIPTION PROCESS AND APPARATUSBiotechnologyModernaTX, Inc.
Dec 4, 20252025/0367278VARIANT STRAIN-BASED CORONAVIRUS VACCINESPharmaceuticalsModernaTX, Inc.
Nov 27, 20252025/0362278MASS SPECTROMETRY OF MRNAMeasurementModernaTX, Inc.
Nov 27, 20252025/0360194HERPES SIMPLEX VIRUS MRNA VACCINESPharmaceuticalsModernaTX, Inc.
Nov 6, 20252025/0340586PREPARATION OF HIGHLY CONCENTRATED MRNAPharmaceuticalsModernaTX, Inc.
Oct 9, 20252025/0313830MESSENGER RIBONUCLEIC ACIDS WITH EXTENDED HALF-LIFEBiotechnologyModernaTX, Inc.
Oct 9, 20252025/0312442EPSTEIN-BARR VIRUS VACCINESPharmaceuticalsModernaTX, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 94 · Biotechnology 28 · Organic fine chemistry 8 · Chemical engineering 3 · Basic materials chemistry 1 · Analysis of biological materials 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton MRNA · research, not advice